Expert digest
Credentialed experts on podcasts, in newsletters and at conferences, paraphrased with verbatim quotes, tier-coded for citation rigour.
BPC-157 in Q2 2026: what actually changed
The FDA removed BPC-157 from Category 2 in April 2026 and scheduled a PCAC review for July. The regulatory pathway shifted. The evidence picture did not.
CJC-1295 Q2 2026: what changed this quarter
CJC-1295 remains unapproved. The FDA's PCAC meets in July 2026 but CJC-1295 is not on its agenda. Two 2026 reviews confirm the clinical evidence has not moved.
Ipamorelin Q2 2026: what changed
Quarterly ipamorelin review: the HHS reclassification announcement, a still-pending FDA Category 1 move, and no new trial data.
PT-141 Q2 2026: the obesity pivot
Bremelanotide entered the obesity combination space this quarter. BMT-801 phase 2 data and next-generation MC4R compounds reshape the PT-141 picture.
What experts said about Semax this quarter
Three preclinical studies, a gerontology review and an FDA compounding meeting. What researchers published on Semax in Q2 2026.
What experts said about TB-500 in Q2 2026
On-record expert commentary on TB-500 from Q2 2026: three orthopaedic reviews, Topol's cancer-biology warning, and the upcoming FDA PCAC review.
Tesamorelin: what experts said, Q2 2026
Tesamorelin has one FDA approval and plenty of off-label hype. Here is what named experts said this quarter.
What experts said about BPC-157 in Q2 2026
A digest of on-record expert commentary on BPC-157 from Q2 2026, with credentials, conflicts of interest, and the evidence gaps each expert flagged.
What experts said about CJC-1295 in Q2 2026
On-record expert commentary on CJC-1295 from Q2 2026: the evidence gap, cancer-risk concerns, regulatory shifts, and the upcoming PCAC review.
Ipamorelin: what experts said, Q2 2026
On-record expert commentary on ipamorelin from Q2 2026, with credentials, conflicts of interest, and the FDA regulatory picture.
What experts said about PT-141 in Q2 2026
On-record expert commentary on PT-141 from Q2 2026: arguments for male trials, a Harvard meta-analysis, and Palatin's obesity pivot.
What Penn Medicine's 'food noise' case study actually showed
Casey Halpern's Nature Medicine case study recorded nucleus-accumbens activity in a single patient on tirzepatide. Activity was suppressed early, then returned at 5 months alongside renewed cravings.